TuHURA Biosciences, Inc./NV (HURA) Q3 2025 10-Q Quarterly Report
TuHURA Biosciences, Inc./NV (HURA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 14, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
TuHURA Biosciences, Inc./NV Q3 2025 10-Q Analysis
Risk Factors
- • New risk added: clinical hold lifted by FDA for Phase 3 trial of IFx-2.0 triggered milestone-based private placement funding of $12.6M in June 2025
- • Material update: Kineta Merger closed June 30, 2025, adding TBS-2025 asset and changing product pipeline and operational scope significantly
- • Regulatory risk: reliance on FDA’s accelerated approval pathway for IFx-2.0 Phase 3 Merkel cell carcinoma trial initiated June 2025
- • Operational risk: increased research and development expenses to $14.5M for 9M 2025 from $9.4M in prior year, driven by clinical and personnel cost rises
- • Financial risk: cash and cash equivalents at $2.7M as of September 30, 2025, with a $3M secured promissory note facility maturing December 31, 2025
TuHURA Biosciences, Inc./NV Q3 2025 Quarterly FinancialsXBRL
Revenue
$0
Net Income
-$7M
▲ +25.4% QoQ
ROE
-42.3%
Total Assets
$26M
EPS (Diluted)
$-0.14
▲ +33.3% QoQ
Operating Cash Flow
-$11M
▼ -77.4% QoQ
Source: XBRL data from TuHURA Biosciences, Inc./NV Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on TuHURA Biosciences, Inc./NV
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.